Literature DB >> 20523131

Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis.

Mysore K Sudarshan1, Bilagumba Gangaboraiah, Haradanahalli S Ravish, Doddabele H Ashwath Narayana.   

Abstract

The metadata of 10 published studies and 3 vaccine trial reports comprising of 19 vaccine cohorts from four countries conducted over a period of 23 years (1986 - 2009) was used for metaanalysis. The vaccines studied were purified chick embryo cell vaccine (Rabipur, India & Germany), purified vero cell rabies vaccine (Verorab, France; Indirab, India) & human diploid cell vaccine (MIRV, France).The potency of these vaccines varied from 0.55 IU to 2.32 IU per intradermal dose of 0.1 ml per site. The vaccines were administered to 1,011 subjects comprising of 19 cohorts and using five different ID regimens. The immunogenicity was measured by assays of rabies virus neutralizing antibody (RVNA) titres using rapid fluorescent focus inhibition test (RFFIT) [15 cohorts] and mouse neutralization test (MNT) [4 cohorts]. The statistical analysis of the data was done by Karl Pearson's correlation coefficient to measure the relationship between antigenicity and immunogenicity. It was revealed that, there was no significant linear relationship between antigenicity and immunogenicity of rabies vaccines when administered by intradermal route. (p> 0.230 and p>0.568).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20523131      PMCID: PMC3322518          DOI: 10.4161/hv.6.7.11934

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  14 in total

1.  Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine.

Authors:  Jiri Beran; Karel Honegr; Angelika Banzhoff; Claudius Malerczyk
Journal:  Vaccine       Date:  2005-04-06       Impact factor: 3.641

2.  Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.

Authors:  Arvydas Ambrozaitis; Alvydas Laiskonis; Ligita Balciuniene; Angelika Banzhoff; Claudius Malerczyk
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

3.  Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine.

Authors:  U Charanasri; V Meesomboon; D Kingnate; P Samuthananon; W Chaeychomsri
Journal:  J Med Assoc Thai       Date:  1992-11

4.  Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial.

Authors:  J Lang; D Q Hoa; N V Gioi; N C Vien; C V Nguyen; N Rouyrre; R Forrat
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Mar-Apr       Impact factor: 2.184

5.  Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine.

Authors:  D J Briggs; A Banzhoff; U Nicolay; S Sirikwin; B Dumavibhat; S Tongswas; C Wasi
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

6.  Postexposure treatment of rabies infection: can it be done without immunoglobulin?

Authors:  Henry Wilde; Pakamatz Khawplod; Thiravat Hemachudha; Visith Sitprija
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

7.  Evaluation of a new five-injection, two-site,intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open-label, active-controlled trial in healthy adult volunteers in India.

Authors:  M K Sudarshan; S N Madhusudana; B J Mahendra; D H Ashwath Narayana; M S Ananda Giri; O Popova; H B Vakil
Journal:  Curr Ther Res Clin Exp       Date:  2005-07

8.  Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines. Results of a meta-analysis.

Authors:  M K Sudarshan; B J Mahendra; S N Madhusudana; D H Ashwath Narayana; T V Sanjay; M S Anandagiri
Journal:  Hum Vaccin       Date:  2005-09-18

9.  Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML.

Authors:  Shampur N Madhusudana; Thitamaranahalli V Sanjay; Bangalore J Mahendra; Mysore K Sudarshan; Doddabele H Ashwath Narayana; Anand Giri; Kader Muhamuda; Vasanthapuram Ravi; Hoshang B Vakil; Cladius Malerczyk
Journal:  Hum Vaccin       Date:  2006 Sep-Oct

10.  Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study.

Authors:  D B Fishbein; R E Pacer; D F Holmes; A B Ley; P Yager; T C Tong
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

View more
  4 in total

1.  Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China.

Authors:  Quan Hu; Man-Qing Liu; Zheng-Gang Zhu; Ze-Rong Zhu; Sha Lu
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

Review 2.  Prevention and control of neglected tropical diseases: overview of randomized trials, systematic reviews and meta-analyses.

Authors:  Shanthi Kappagoda; John P A Ioannidis
Journal:  Bull World Health Organ       Date:  2014-03-13       Impact factor: 9.408

3.  Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine.

Authors:  Marc Pearton; Daniela Pirri; Sang-Moo Kang; Richard W Compans; James C Birchall
Journal:  Adv Healthc Mater       Date:  2013-04-08       Impact factor: 9.933

4.  Demographics of animal bite victims & management practices in a tertiary care institute in Mumbai, Maharashtra, India.

Authors:  N J Gogtay; A Nagpal; A Mallad; K Patel; S J Stimpson; A Belur; U M Thatte
Journal:  Indian J Med Res       Date:  2014-03       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.